Angiogenic T cells are decreased in rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 74, Issue 5, 2015, Pages 921-927

  Rodríguez Carrio, Javier ^a   Alperi López, Mercedes ^b   López, Patricia ^a   Alonso Castro, Sara ^b   Ballina García, Francisco J ^b   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ANGIOGENIC T CELL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CELL INTERACTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DIABETES MELLITUS; DISEASE ACTIVITY; DYSLIPIDEMIA; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM; FEMALE; FLOW CYTOMETRY; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE REGRESSION; OBESITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMOKING; T LYMPHOCYTE; TISSUE REPAIR; AGED; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; IMMUNOLOGY; LYMPHOCYTE COUNT; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENDOTHELIAL PROGENITOR CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PHYSIOLOGIC; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 84926652489     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204250     Document Type: Article

References (45)

1. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
2. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
3. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-32.
4. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
5. Innala L, Moller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13:R131.
6. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
7. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999;26:2562-71.
8. Rodriguez-Rodriguez L, Lopez-Mejias R, Garcia-Bermudez M, et al. Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012;2012:574817.
9. Lopez-Mejias R, Garcia-Bermudez M, Gonzalez-Juanatey C, et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012;224:426-9.
10. Pompilio G, Capogrossi MC, Pesce M, et al. Endothelial progenitor cells and cardiovascular homeostasis: clinical implications. Int J Cardiol 2009;131:156-67.
11. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
12. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
13. Hur J, Yang HM, Yoon CH, et al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation 2007;116:1671-82.
14. Rouhl RP, Mertens AE, van Oostenbrugge RJ, et al. Angiogenic T-cells and putative endothelial progenitor cells in hypertension-related cerebral small vessel disease. Stroke 2012;43:256-8.
15. Ronnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011;116:227-37.
16. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-15.
17. Lood C, Amisten S, Gullstrand B, et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 2010;116:1951-7.
18. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69.
19. Thacker SG, Zhao W, Smith CK, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012;64:2975-85.
20. Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 2012;7:e37000.
21. Rodriguez-Carrio J, de Paz B, López P, et al. IFNa serum levels are associated with EPC imbalance and disease features in Rheumatoid Arthritis patients. PLOS ONE 2013. In press. doi:10.1371/journal.pone.0086069
22. Gonzalez A, Maradit KH, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008;67:64-9.
23. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, et al. TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011;216:125-30.
24. Rodriguez-Carrio J, Prado C, de PB, et al. Circulating endothelial cells and their progenitors in systemic lupus erythematosus and early rheumatoid arthritis patients. Rheumatology (Oxford) 2012;51:1775-84.
25. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
26. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
27. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.
28. Tomasson G, Aspelund T, Jonsson T, et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010;69:1649-54.
29. Lopez-Longo FJ, Oliver-Minarro D, del T I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24.
30. Grainger DJ, Bethell HW. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis 2002;61:110-14.
31. Liang KP, Kremers HM, Crowson CS, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009;36:2462-9.
32. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-15.
33. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
34. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008-14.
35. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503.
36. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006;3:e491.
37. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009;18:980-9.
38. Kirou KA, Cole P, Salmon JE, et al. Identification of molecular pathways associated with progression of carotid atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 2013;54(Suppl):S807.
39. Zhao W, Somers EC, McCune WJ, et al. Type I Interferon gene signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 2009;60(Suppl 10):582.
40. Kaplan MJ, Salmon JE. How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum 2011;63:334-6.
41. Kobayashi T, Sato Y, Hasegawa Y, et al. Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon. Intern Med 1992;31:936-40.
42. Kuwata A, Ohashi M, Sugiyama M, et al. A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med Sci 2002;324:331-4.
43. Teragawa H, Hondo T, Amano H, et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996;37:905-15.
44. Turesson C, McClelland RL, Christianson TJ, et al. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:70-5.
45. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96.